Stephen Lemieux
Secretary
Chief Financial Officer
Cipher Pharmaceuticals In
Canada
Biography
Mr. Stephen L. Lemieux, BA, MMPA, CPA, CA has been Chief Operating Officer of Cipher Pharmaceuticals US LLC since May 22, 2017. Mr. Lemieux has been the Chief Financial Officer and Secretary of Cipher Pharmaceuticals Inc. since September 12, 2016 and served as its Chief Operating Officer since May 19, 2017. Mr. Lemieux served as Interim Chief Executive Officer of Cipher Pharmaceuticals US LLC until April 17, 2017 and served as its Chief Financial Officer until May 22, 2017. He served as an Interim Chief Executive Officer of Cipher Pharmaceuticals Inc. from November 11, 2016 to April 17, 2017. Mr. Lemieux served as a Vice President of Crescita Therapeutics Inc. from March 01, 2016 to September 6, 2016 and Chief Financial Officer from January 2012 to September 6, 2016. Mr. Lemieux served as the Chief Financial Officer and Vice President of Nuvo Pharmaceuticals Inc. since January 13, 2012 until September 9, 2016. He served as Vice President of Finance and Corporate Controller at Nuvo Pharmaceuticals Inc. until January 13, 2012. Prior to joining Nuvo in 2007, Mr. Lemieux served as the Corporate Controller at Martinrea International Inc. Prior to joining Martinrea, Mr. Lemieux served as an Assistant Controller at Magna Powertrain (formerly, Tesma International Inc.) (Tesma) and previously served as its Manager, Global Financial Reporting. Prior to joining Tesma, Mr. Lemieux worked for Ernst & Young LLP performing audit, restructuring and accounting work for its clients. He has over 13 years of public company experience. Mr. Lemieux's transactional experience includes licensing and asset sales, debt and equity financing, acquisitions, corporate reorganizations and plans of arrangement. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting from the University of Toronto.
Research Interest
Financial Operations, Information Technology, Manufacturing, Human Resources and Planning.